PDCD1 and cancer: Monoclonal antibodies against another checkpoint modulator, PD-1, such as nivolumab (Bristol-Myers-Squibb, BMS-936558), are also showing preliminary efficacy in clinical trials for a number of cancers, though no objective responses have been observed yet in Phase 1 trials in CRPC patients [33].